People: KaloBios Pharmaceuticals Inc (KBIO.OQ)

KBIO.OQ on NASDAQ Stock Exchange Global Market

0.62USD
1:44pm EDT
Change (% chg)

$0.09 (+16.85%)
Prev Close
$0.53
Open
$0.56
Day's High
$0.64
Day's Low
$0.56
Volume
442,773
Avg. Vol
195,961
52-wk High
$2.44
52-wk Low
$0.37

Search Stocks

Summary

Name Age Since Current Position

Ted Love

56 2014 Independent Chairman of the Board

Herbert Cross

43 2015 Interim Chief Executive Officer, Chief Financial Officer, Principal Financial and Accounting Officer

Geoffrey Yarranton

2006 Chief Scientific Officer, Executive Vice President - Research and Development

Donald Joseph

2013 Chief Legal Officer

Laurie Alsup

60 2013 Director

Robert Baffi

60 2014 Director

Ronald Martell

51 2015 Director

Denise Gilbert

57 2008 Independent Director

Gary Lyons

64 2011 Independent Director

Raymond Withy

59 2005 Independent Director

Biographies

Name Description

Ted Love

Dr. Ted W. Love, M.D., is an Independent Chairman of the Board of KaloBios Pharmaceuticals Inc. Dr. Love has been a member of our board of directors since March 2009. He has held senior executive and management positions at a number of biopharmaceutical companies including Onyx Pharmaceuticals, Inc., Nuvelo, Inc., Theravance, Inc. and Genentech, Inc. Dr. Love also serves or has served as a member of the boards of directors of biopharmaceutical companies Santarus, Inc., Amicus, Inc., Adventrx, Inc., Affymax, Inc. and BioRad, Inc. and serves on the board of directors of Stanford Hospital & Clinics.

Herbert Cross

Mr. Herbert C. Cross is Interim Chief Executive Officer, Chief Financial Officer, Principal Financial and Accounting Officer of KaloBios Pharmaceuticals, Inc. Mr. Cross joins the Company from Affymax, Inc. (“Affymax”), a public biopharmaceutical company, which he joined in November 2010 as Vice President, Finance and Chief Accounting Officer. Mr. Cross has served as Chief Financial Officer of Affymax from February 2011 until June 2013. Prior to joining Affymax, Mr. Cross was vice president, finance for Facet Biotech Corporation (“Facet Biotech”), a public biotechnology company, from December 2008 to October 2010. Prior to Facet Biotech, Mr. Cross was corporate controller at PDL BioPharma, Inc. (“PDL BioPharma”), a public biopharmaceutical company, from October 2006 to December 2008. Prior to PDL BioPharma, Mr. Cross served in various positions, including vice president, finance, at Neoforma, Inc., a public e-commerce software company, and as manager, Assurance and Business Advisory Services at Arthur Andersen LLP. Mr. Cross earned a B.S. from the Haas School of Business at the University of California, Berkeley.

Geoffrey Yarranton

Dr. Geoffrey T. Yarranton, Ph.D., is Chief Scientific Officer, Executive Vice President - Research and Development of KaloBios Pharmaceuticals Inc. Prior to this, he co-founded Celscia Therapeutics in 2003 and served as Chief Executive Officer before merging Celscia with KaloBios in 2004. Following the merger, Dr. Yarranton served as the Chief Executive Officer of KaloBios from 2004 to 2006 and as a member of our Board from 2004 to 2009. Dr. Yarranton has over 30 years of experience in the biotechnology industry working both in Europe and the United States. Prior to co-founding Celscia, Dr. Yarranton served as Senior Vice President of Research and Development at Coulter Pharmaceutical. Following the acquisition of Coulter Pharmaceutical by Corixa Corporation, Dr. Yarranton became Senior Vice President of Research and Development and Site Director of the South San Francisco site. Dr. Yarranton spent 16 years at Celltech Therapeutics in the United Kingdom, where he led their research activities as the Director of Research. Dr. Yarranton holds a Bachelor of Science degree in biology from the University of Leicester in the United Kingdom and a Ph.D. in the enzymology of DNA replication, from the National Institute for Medical Research, United Kingdom.

Donald Joseph

Mr. Donald R. Joseph is Chief Legal Officer of KaloBios Pharmaceuticals, Inc. Mr. Joseph has 20 years of biopharmaceutical industry experience, including major global health non-profit organizations. Prior to KaloBios, he was Chief Executive Officer of BIO Ventures for Global Health (BVGH), a non-profit organization engaging private industry in global health initiatives, from February to November 2012 and Chief Operating Officer from April 2010 to January 2012. He is currently Chairman of the BVGH board of directors. He has also served as Chief Operating Officer at the Institute for OneWorld Health, a non-profit drug development company. In both organizations, he was also responsible for the legal function in addition to his other responsibilities. He previously served as general counsel, corporate secretary, and in other senior management roles at biopharmaceutical companies, including Abgenix, Inc., which was acquired by Amgen Inc., and Renovis Inc., a former subsidiary of Evotec AG. Before entering the life sciences industry, Mr. Joseph practiced business law for a number of years in major firms, including as an international partner at Baker & McKenzie, one of the world's largest law firms. Mr. Joseph received his J.D. degree from the University of Texas School of Law, with honors.

Laurie Alsup

Dr. Laurie Smaldone Alsup has over 25 years of global leadership experience in the pharmaceutical and biotechnology industries. Currently, Dr. Smaldone Alsup is President and Chief Scientific Officer of PharmApprove, a regulatory communications consultancy firm. Dr. Smaldone Alsup previously served in clinical and regulatory roles of increasing responsibility and scope while at Bristol Myers Squibb, including Senior Vice President of Global Regulatory Science, Vice President of Infectious Diseases Clinical Research, and also as Director of Cancer Clinical Research. In addition, she served as CEO of Phytomedics, an early stage biopharmaceutical company focused on arthritis and inflammation. Dr. Smaldone Alsup received her M.D. degree at Yale University, where she completed her residency in Internal Medicine and fellowship in Medical Oncology.She is Director of the Company.

Robert Baffi

Dr. Robert A. Baffi, Ph.D. is Director of Company. Dr. Baffi currently serves as Executive Vice President of Technical Operations at BioMarin Pharmaceutical Inc. (“BioMarin”), where he is responsible for overseeing manufacturing, process development, quality, analytical chemistry and logistics departments. From May 2000 to December 2009, Dr. Baffi served as Senior Vice President of Technical Operations at BioMarin. From 1986 to 2000, Dr. Baffi served in a number of positions with increasing responsibility at Genentech Inc. (“Genentech”), primarily in the functional area of quality control. Prior to joining Genentech, Dr. Baffi worked for Cooper BioMedical as a research scientist and at Becton Dickinson Research Center as a post-doctoral fellow. Dr. Baffi has contributed to more than 20 regulatory submissions for product approval in the United States and Europe and to more than 20 regulatory submissions for investigational new drug testing. Dr. Baffi received a Ph.D., M. Phil and a B.S. in biochemistry from the City University of New York and an M.B.A. from Regis University.

Ronald Martell

Mr. Ronald A. Martell is an Director of the Company. Mr. Martell has more than 25 years’ experience building and managing unique businesses in the biotech industry, and most recently served as Chief Executive Officer at Sevion Therapeutics, prior to which he held similar roles at NeurogesX and at Poniard Pharmaceuticals. Earlier in his career Mr. Martell served as Senior Vice President of Commercial Operations at ImClone Systems, where he built ImClone Systems’ worldwide commercial operations and field sales force to market and commercialize Erbitux® with partners Bristol-Myers Squibb and Merck KGaA. Prior to joining ImClone Systems, Mr. Martell worked for more than 10 years at Genentech in a variety of leadership positions, the last of which was Group Manager, Oncology. At Genentech, he was responsible for building the company’s oncology franchise including the launch of Herceptin® for metastatic HER-2 positive breast cancer and Rituxan® for non-Hodgkin’s lymphoma. Mr. Martell began his career at Roche Pharmaceuticals.

Denise Gilbert

Dr. Denise M. Gilbert, Ph.D., is Independent Director of KaloBios Pharmaceuticals Inc. Dr. Gilbert is a retired senior life science industry executive and has been serving as a director of various public and private life science companies since 2002. Previously, she served as chief executive officer of Entigen Corporation, a private life science information technology company, from 2001 to 2002. In addition, Dr. Gilbert has served as chief financial officer of two public life science companies, Incyte Pharmaceuticals Inc. from 1995 to 1999 and Affymax NV from 1993 until its sale to Glaxo in 1995. Dr. Gilbert started her career in biotechnology in 1984, first in venture capital and then as a senior biotechnology analyst with Smith Barney Harris & Upham and Montgomery Securities. She is currently on the Board and chair of the audit committees of Cytokinetics, Inc. and Dynavax Technologies Corporation. Dr. Gilbert holds a Bachelor of Arts from Cornell University and a Ph.D. in cell and development biology from Harvard University. Our Board determined that Ms. Gilbert should serve as a director based on her experience as a senior executive in the life science industry, as well as her experience and skills relating to financial statement and accounting matters.

Gary Lyons

Mr. Gary A. Lyons is an Independent Director of KaloBios Pharmaceuticals Inc. Mr. Lyons served as President, Chief Executive Officer and member of the board of directors of Neurocrine Biosciences, Inc., a public biotechnology company, from February 1993 to March 2008. Since March 2008, Mr. Lyons has served as President of GL Biomed, a life science consulting and advisory firm he founded. Prior to joining Neurocrine, Mr. Lyons held a number of senior management positions at Genentech, Inc., including Vice President of Business Development, Vice President of Sales, and Director of Sales and Marketing. In addition to serving on board of directors, he also serves on the boards of directors of Neurocrine Biosciences, Rigel Pharmaceuticals, Inc., Neurogesx, and Vical Incorporated, and he previously served on the boards of directors of Poniard Pharmaceuticals, Inc., Facet Biotech Corporation, and PDL BioPharma, Inc. Mr. Lyons holds a Bachelor of Science in marine biology from the University of New Hampshire and a Master of Business Administration from Northwestern University’s J.L. Kellogg Graduate School of Management.

Raymond Withy

Dr. Raymond M. Withy, Ph.D., is Independent Director of KaloBios Pharmaceuticals Inc. Dr. Withy has been self-employed as a consultant since May 2005. Dr. Withy has over 20 years of experience in the biotechnology industry. As one of the co-founders of Abgenix in 1996, Dr. Withy initially served as its Vice-President, Business Development, and subsequently its Chief Business Officer and President and Chief Executive Officer until his retirement in 2004. Prior to the founding of Abgenix, Dr. Withy held various business development positions at Cell Genesys, Inc. From 1991 to 1993, Dr. Withy was a consultant to the industry in the areas of business development and strategic planning. Previously, Dr. Withy held various research and development positions at Genzyme Corp. and Integrated Genetics. Dr. Withy has served as a member of the Board of a number of companies, including Xenotech, Inc., Abgenix, Digitab, Inc. and Nuon Therapeutics, Inc. Dr. Withy served as the chairman of the boards of directors of Nuon Therapeutics, Inc. and Digitab, Inc. Dr. Withy received a Bachelor of Science in Chemistry and Biochemistry and a Ph.D. in Biochemistry from the University of Nottingham, U.K. and was a post-doctoral research fellow at the California Institute of Technology. Our Board determined that Dr. Withy should serve as a director based on his extensive experience in the biotechnology industry, including his experience in management, business development, research, and strategic planning.

Basic Compensation

Search Stocks